ELVN vs. REPYY
ELVN (Enliven Therapeutics Inc.) and REPYY (Repsol SA) are both stocks. ELVN operates in Biotechnology (Healthcare), while REPYY operates in Oil & Gas Integrated (Energy). Over the past 5 years, ELVN returned 2.00%/yr vs 21.37%/yr for REPYY. At a 0.10 correlation, their price movements are largely independent.
Performance
ELVN vs. REPYY - Performance Comparison
Loading charts...
Returns By Period
In the year-to-date period, ELVN achieves a 133.96% return, which is significantly higher than REPYY's 49.15% return.
ELVN
- 1D
- 1.44%
- 1M
- -13.41%
- YTD
- 133.96%
- 6M
- 71.57%
- 1Y
- 64.82%
- 3Y*
- 18.69%
- 5Y*
- 2.00%
- 10Y*
- —
REPYY
- 1D
- 1.46%
- 1M
- 0.80%
- YTD
- 49.15%
- 6M
- 45.64%
- 1Y
- 110.63%
- 3Y*
- 31.86%
- 5Y*
- 21.37%
- 10Y*
- 14.09%
ELVN vs. REPYY - Yearly Performance Comparison
| 2026 (YTD) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|---|---|---|
ELVN Enliven Therapeutics Inc. | 133.96% | -31.56% | 62.57% | -15.40% | 81.78% | -89.80% | 47.00% |
REPYY Repsol SA | 49.15% | 66.69% | -13.03% | -2.01% | 41.58% | 20.97% | 36.06% |
Correlation
The correlation between ELVN and REPYY is -0.05, meaning there is essentially no relationship between their price movements. Each responds to its own set of market drivers, making them strong candidates for combining in a diversified portfolio.
| Correlation | |
|---|---|
Correlation (1Y) Calculated over the trailing 1-year period | -0.05 |
Correlation (3Y) Calculated over the trailing 3-year period | 0.07 |
Correlation (5Y) Calculated over the trailing 5-year period | 0.09 |
Correlation (All Time) Calculated using the full available price history since Mar 13, 2020 | 0.10 |
The correlation between ELVN and REPYY shifts across timeframes, from -0.05 (1 year) to 0.10 (all time), reflecting how their relationship changes across market environments.
Fundamentals
ELVN:
$2.26B
REPYY:
$30.61B
ELVN:
-$1.69
REPYY:
$2.16
ELVN:
4.99
REPYY:
1.17
ELVN:
$0.00
REPYY:
$55.91B
ELVN:
-$46.00K
REPYY:
$10.82B
ELVN:
-$110.65M
REPYY:
$6.32B
Compare stocks, funds, or ETFs
Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.
Return for Risk
ELVN vs. REPYY — Risk / Return Rank
ELVN
REPYY
ELVN vs. REPYY - Risk-Adjusted Trends Comparison
This table presents a comparison of risk-adjusted performance metrics for Enliven Therapeutics Inc. (ELVN) and Repsol SA (REPYY). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.
| ELVN | REPYY | Difference | |
|---|---|---|---|
| Sharpe ratioReturn per unit of total volatility | -3.00 | ||
| Sortino ratioReturn per unit of downside risk | -2.09 | ||
| Omega ratioGain probability vs. loss probability | 1.22 | 1.57 | -0.36 |
| Calmar ratioReturn relative to maximum drawdown | 1.77 | 6.43 | -4.66 |
| Martin ratioReturn relative to average drawdown | 4.61 | 21.36 | -16.74 |
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month. | |||
Loading charts...
Sharpe Ratios by Period
| ELVN | REPYY | Difference | |
|---|---|---|---|
Sharpe Ratio (1Y)Calculated over the trailing 1-year period | 0.80 | 3.81 | -3.00 |
Sharpe Ratio (5Y)Calculated over the trailing 5-year period | 0.02 | 0.75 | -0.73 |
Sharpe Ratio (10Y)Calculated over the trailing 10-year period | — | 0.44 | — |
Sharpe Ratio (All Time)Calculated using the full available price history | -0.09 | 0.46 | -0.55 |
Drawdowns
ELVN vs. REPYY - Drawdown Comparison
The maximum ELVN drawdown since its inception was -98.20%, which is greater than REPYY's maximum drawdown of -65.56%. Use the drawdown chart below to compare losses from any high point for ELVN and REPYY.
Loading charts...
Drawdown Indicators
| ELVN | REPYY | Difference | |
|---|---|---|---|
Max DrawdownLargest peak-to-trough decline | -98.20% | -65.56% | -32.64% |
Max Drawdown (1Y)Largest decline over 1 year | -36.84% | -17.30% | -19.54% |
Max Drawdown (3Y)Largest decline over 3 years | -56.05% | -34.63% | -21.42% |
Max Drawdown (5Y)Largest decline over 5 years | -89.05% | -35.71% | -53.34% |
Max Drawdown (10Y)Largest decline over 10 years | — | -65.56% | — |
Current DrawdownCurrent decline from peak | -83.58% | -5.36% | -78.22% |
Average DrawdownAverage peak-to-trough decline | -84.22% | -15.98% | -68.24% |
Ulcer IndexDepth and duration of drawdowns from previous peaks | 14.09% | 5.20% | +8.89% |
Volatility
ELVN vs. REPYY - Volatility Comparison
Enliven Therapeutics Inc. (ELVN) has a higher volatility of 14.50% compared to Repsol SA (REPYY) at 9.74%. This indicates that ELVN's price experiences larger fluctuations and is considered to be riskier than REPYY based on this measure. The chart below showcases a comparison of their rolling one-month volatility.
Loading charts...
Volatility by Period
| ELVN | REPYY | Difference | |
|---|---|---|---|
Volatility (1M)Calculated over the trailing 1-month period | 14.50% | 9.74% | +4.76% |
Volatility (6M)Calculated over the trailing 6-month period | 60.61% | 25.08% | +35.53% |
Volatility (1Y)Calculated over the trailing 1-year period | 82.50% | 29.25% | +53.25% |
Volatility (5Y)Calculated over the trailing 5-year period, annualized | 85.81% | 28.48% | +57.33% |
Volatility (10Y)Calculated over the trailing 10-year period, annualized | 87.95% | 32.31% | +55.64% |
Dividends
ELVN vs. REPYY - Dividend Comparison
ELVN has not paid dividends to shareholders, while REPYY's dividend yield for the trailing twelve months is around 4.30%.
| Position | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|---|
ELVN Enliven Therapeutics Inc. | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
REPYY Repsol SA | 4.30% | 5.69% | 8.07% | 5.03% | 4.22% | 2.41% | 8.21% | 8.35% | 2.97% | 4.31% | 3.89% |
Financials
ELVN vs. REPYY - Financials Comparison
This section allows you to compare key financial metrics between Enliven Therapeutics Inc. and Repsol SA. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.
Total Revenue: Total amount of money received from sales and other business activities
Frequently Asked Questions
ELVN and REPYY have a correlation of -0.05, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.
ELVN has higher volatility (14.50%) compared to REPYY (9.74%). In terms of maximum drawdown, ELVN dropped -98.20% vs REPYY's -65.56%.
REPYY currently has the higher Sharpe Ratio (3.81 vs 0.80), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.
Find the right allocation for ELVN and REPYY
Add both to a portfolio and optimize allocations for your target — whether that's maximizing returns, minimizing drawdowns, or balancing risk across holdings.
Open Portfolio Optimizer